Skip to main content
Midas Edge

Serina Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

SER$1.430.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

Series A Convertible Preferred Stock · Common Stock · AdditionalPaid-In Capital · AccumulatedOtherComprehensiveLoss · Accumulated Deficit · Total Stockholders’Equity (Deficit)
Numberof Shares · Amount · Numberof Shares · Par Value
BALANCE AT DECEMBER 31, 2025965$4,94010,767$1$58,536$(14)$(63,500)$(37)
Issuance of common stock upon exercise of stock options——138—8——8
Issuance of common stock under At The Market sales agreement, net of issuance costs of $234——3,109—10,169——10,169
Issuance of common stock and warrants in connection with private placement, net of issuance cost of $120 and tranche liability of $3,282——422—11,598——11,598
Issuance of common stock and warrants in connection with private placement and reclassification of tranche liability of $705——444—1,705——1,705
Issuance of common stock for Series A Convertible Preferred stock dividends——19—————
Stock-based compensation————1,077——1,077
Foreign currency translation adjustment—————6—6
Net loss——————(6,898)(6,898)
BALANCE AT MARCH 31, 20269654,94014,899183,093(8)(70,398)17,628
Issuance of common stock upon exercise of stock options——10—1——1
Issuance of common stock for Series A Convertible Preferred stock conversion(965)(4,940)2,22214,939———
Issuance of common stock for Series A Convertible Preferred stock dividends——19—————
Issuance of common stock and warrants in connection with private placement, net of issuance cost of $3 and reclassification of tranche liability of $1,200——89—6,397——6,397
Issuance of common stock upon exercise of prefunded warrants in connection with private placement——8,1611———1
Stock-based compensation————1,051——1,051
Foreign currency translation adjustment—————8—8
Net loss——————(6,356)(6,356)
BALANCE AT JUNE 30, 2026—$—25,400$3$95,481$—$(76,754)$18,730

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Series A Convertible Preferred Stock · Common Stock · Additional Paid-InCapital · Total Stockholders’Equity
Numberof Shares · Amount · Numberof Shares · ParValue · Accumulated Deficit · Noncontrolling Interest
BALANCE AT DECEMBER 31, 2024—$—9,422$1$44,958$(44,318)$(133)$508
Issuance of common stock upon exercise of stock options——10—1——1
Issuance of common stock to Juvenescence, net of issuance costs——500—4,916——4,916
Stock-based compensation————956——956
Net loss—————(4,813)(9)(4,822)
BALANCE AT MARCH 31, 2025——9,932150,831(49,131)(142)1,559
Issuance of common stock upon exercise of stock options——42—1——1
Issuance of Series A Convertible Preferred Stock, net of issuance costs of $609654,940—————4,940
Issuance of common stock under At The Market sales agreement, net of issuance costs of $114——124—629——629
Issuance of common stock to consultant for services rendered——42—60——60
Release of restricted stock units to consultant for services rendered——5—29——29
Stock-based compensation————890——890
Net loss—————(6,448)(14)(6,462)
BALANCE AT JUNE 30, 2025965$4,94010,145$1$52,440$(55,579)$(156)$1,646
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.